Skip to main content
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc. — Investor Relations & Filings

Ticker · 2500 ISIN · CNE100003PJ8 HKEX Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-04-29 Environmental & Social …
Country HK Hong Kong
Listing HKEX 2500

About Venus Medtech (Hangzhou) Inc.

http://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. is an innovation-driven medical device company specializing in the research, development, manufacturing, and commercialization of transcatheter solutions for structural heart diseases. The company focuses on bioprosthetic heart valves, establishing a comprehensive pipeline that addresses aortic, pulmonary, mitral, and tricuspid valve diseases. Its product portfolio includes transcatheter aortic valve replacement (TAVR) solutions, and it is committed to addressing unmet demand in TPVR and TMVR. The company also develops solutions for hypertension, such as renal artery denervation ablation, and related surgical accessory products. Its products are commercialized globally, reaching over 60 countries and regions across Asia, Europe, and the Americas.

Recent filings

Filing Released Lang Actions
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 100% confidence The document is titled as an environmental, social and governance (ESG) report for the year 2023, covering the company's ESG performance, management structure, stakeholder engagement, materiality analysis, and quality control. It references compliance with ESG reporting guidelines and is approved by the Board of Directors. The content is focused on ESG factors rather than financial results or corporate governance rules. It is a comprehensive report on ESG performance, not an announcement or a brief summary. Therefore, it fits the category of Environmental & Social Information (SR).
2024-04-29 English
2023 ANNUAL REPORT
Annual Report Classification · 100% confidence The document contains detailed sections typical of a comprehensive annual report, including Corporate Information, Chairman's Statement, Financial Summary, Management Discussion and Analysis, Directors' Report, Corporate Governance Report, Independent Auditor's Report, and full consolidated financial statements with notes. The presence of a full set of financial statements and extensive narrative commentary for the fiscal year ended December 31, 2023, indicates this is the official yearly report covering company activity and full financial performance. The document length (15,000 characters) and content confirm it is not a brief announcement or a certification. Therefore, the document is classified as an Annual Report (10-K). FY 2023
2024-04-29 English
VOLUNTARY ANNOUNCEMENT FURTHER UPDATE ON THE UNAUTHORIZED LOANS AND PLEDGED DEPOSITS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Venus Medtech (Hangzhou) Inc. providing an update on unauthorized loans and pledged deposits, including details about the release of pledged deposits and ongoing negotiations regarding loan repayment. It also mentions the continued suspension of trading of the company's shares. The document is relatively short (3361 characters) and is an announcement rather than a full financial report or detailed audit. It does not contain financial statements or comprehensive financial data. It is not a regulatory certification or officer attestation. The content focuses on a specific financial issue update and trading suspension notice, which fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-04-16 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 March 2024. It details movements in authorised/registered share capital, issued shares, share options, and confirmations related to securities issued by the company. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share issuance movements for a specific month. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report publication but a regulatory filing of share capital movements. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-03 English
Notification Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Regulatory Filings Classification · 95% confidence The document is a letter from Venus Medtech (Hangzhou) Inc. addressed to non-registered shareholders regarding the arrangement for electronic dissemination of corporate communications. It explains the company's adoption of electronic delivery of documents such as annual reports, interim reports, notices of meetings, circulars, and proxy forms. The document includes instructions on how shareholders can receive these communications electronically or in printed form, and contains a reply form for shareholders to request printed copies. There is no actual financial data, financial statements, or detailed report content included. The document is informational and administrative in nature, notifying shareholders about the method of receiving corporate communications rather than presenting any financial results or reports. It is not an Annual Report, Interim Report, Earnings Release, or any other substantive financial filing. It also does not report voting results, management changes, or legal proceedings. Given the content and purpose, this document fits the category of Regulatory Filings (RNS) as a general regulatory announcement about corporate communication procedures and compliance with listing rules.
2024-04-02 English
Notification Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Regulatory Filings Classification · 95% confidence The document is a letter from Venus Medtech (Hangzhou) Inc. to its shareholders regarding the arrangement for electronic dissemination of corporate communications. It explains the company's adoption of electronic delivery for documents such as annual reports, interim reports, notices of meetings, circulars, and proxy forms. The letter solicits shareholders' email addresses to receive these communications electronically and provides instructions on how to opt in or out of electronic delivery. There is no actual financial data, financial statements, or detailed report content included. Instead, it is an announcement about how future reports and communications will be distributed. The document is lengthy but serves as a notification and solicitation letter rather than a report or financial filing itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification about corporate communication practices, not an Annual Report (10-K), Interim Report (IR), or Report Publication Announcement (RPA) since it does not announce the publication of a specific report but rather the method of dissemination for future communications.
2024-04-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.